A Phase I/II Study of Lenalidomide and Obinutuzumab (GA101) in Relapsed Indolent Non-Hodgkin's Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Lenalidomide (Primary) ; Obinutuzumab (Primary)
- Indications B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- 11 Sep 2017 Planned End Date changed from 1 May 2018 to 1 May 2019.
- 11 Sep 2017 Planned primary completion date changed from 1 May 2018 to 1 May 2019.
- 06 Jun 2017 Results (n=36) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology